A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2013-203
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-Aml Cells

PLoS ONE
Multidisciplinary
2013English

Crotonoside Exhibits Selective Post-Inhibition Effect in AML Cells via Inhibition of FLT3 and HDAC3/6

Oncotarget
Oncology
2017English

TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Donor HSCs With a Preexisting ASXL1-mutation Led to the Development of FLT3-ITD Positive AML in the Donor and FLT3-ITD Negative AML in the Recipient After Unrelated Transplant

Bone Marrow Transplantation
TransplantationHematology
2018English

Next Generation XPO1 Inhibitor Shows Improved Efficacy and in Vivo Tolerability in Hematologic Malignancies

Blood
BiochemistryImmunologyCell BiologyHematology
2015English

Next-Generation XPO1 Inhibitor Shows Improved Efficacy and in Vivo Tolerability in Hematological Malignancies

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2016English

NOX-driven ROS Formation in Cell Transformation of FLT3-ITD-positive AML

Experimental Hematology
Cancer ResearchGeneticsHematologyMolecular BiologyCell Biology
2016English

BCL2/MDM2 Inhibitor Combo Effective in AML

Cancer Discovery
Oncology
2019English

Mutant IDH2 Inhibitor Looks Promising in AML

Cancer Discovery
Oncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy